UM reports personal fees as consultant and/or from a speakers’ bureau from Boehringer Ingelheim, Roche, Merck Sharpe & Dohme, Amgen, Thermo-Fisher Scientific, Eli Lilly & Company, Diaceutics, GlaxoSmithKline, Merck, AstraZeneca, Janssen, Diatech, Novartis, and Hedera outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.